Meeting of experts on obstructive airway diseases: Targets and methods;Expertentreffen Obstruktive Atemwegserkrankungen: Targets und Methoden

Pneumologie

Volumn 66, Issue 9, 2012, Pages 526-538

  Lorenz, J ^a   Bals, R ^b   Kauczor, H U ^c   Pfeifer, M ^d   Randerath, W ^e   Steinkamp, G ^f   Taube, C ^g   Teschler, H ^h   Welte, T ⁱ   Worth, H ^j  

^a Klinik für Pneumologie Internistische Intensivmedizin   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e Krankenhaus Bethanien Solingen   (Germany)

^f Medizinisch wissenschaftliches Publizieren   (Germany)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j KLINIKUM FÜRTH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DYSPNEA; HUMAN; LUNG PARENCHYMA; MEDICAL EXPERT; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE AIRWAY DISEASE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE;

DIAGNOSTIC IMAGING; GERMANY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; UNITED STATES;

EID: 84865650386     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0032-1310130     Document Type: Conference Paper

References (76)

1. Gershon AS, Warner L, Cascagnette P et al. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet: 2011; 378 991 996
2. McDonough JE, Yuan R, Suzuki M et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med: 2011; 365 1567 1575
3. Mitzner W. Emphysema - a disease of small airways or lung parenchyma? N Engl J Med: 2011; 365 1637 1639
4. Kessler R, Partridge MR, Miravitlles M et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J: 2011; 37 264 272
5. Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax: 2011; 66 764 768
6. Vestbo J, Edwards LD, Scanlon PD et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med: 2011; 365 1184 1192
7. Short PM, Lipworth SI, Elder DH et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ: 2011; 342 d2549
8. Bateman ED, Rabe KF, Calverley PM et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J: 2011; 38 553 560
9. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med: 2011; 365 689 698
10. Waschki B, Kirsten A, Holz O et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest: 2011; 140 331 342
11. Coxson HO, Mayo J, Lam S et al. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2009; 180 588 597
12. Kauczor HU, Wielputz MO, Owsijewitsch M et al. Computed tomographic imaging of the airways in COPD and asthma. J Thorac Imaging: 2011; 26 290 300
13. Owsijewitsch M, Grenier P, Crapo JD. Radiological Society of North America (RSNA) et al. COPD Phenotyping in CT: Comparison of Visual and Densitometric Emphysema Extent Assessment. 2009; SSC04-SSC07
14. Quantitative Airway Analysis on Thin-Section MDCT in Cystic Fibrosis - Correlation with Pulmonary Function Testing. 29 11 2011
15. Han MK, Kazerooni EA, Lynch DA et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology: 2011; 261 274 282
16. Ley-Zaporozhan J, Puderbach M, Kauczor HU. MR for the evaluation of obstructive pulmonary disease. Magn Reson Imaging Clin N Am: 2008; 16 291 308 ix
17. Ley-Zaporozhan J, Ley S, Eberhardt R et al. Visualization of morphological parenchymal changes in emphysema: comparison of different MRI sequences to 3D-HRCT. Eur J Radiol: 2010; 73 43 49
18. Ley-Zaporozhan J, van Beek EJ. Imaging phenotypes of chronic obstructive pulmonary disease. J Magn Reson Imaging: 2010; 32 1340 1352
19. Risse F, Eichinger M, Kauczor HU et al. Improved visualization of delayed perfusion in lung MRI. Eur J Radiol: 2011; 77 105 110
20. van Beek EJ, Dahmen AM, Stavngaard T et al. Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J: 2009; 34 1311 1321
21. Lehmann F, Knitz F, Weiler N et al. [A software tool for analysis and quantification of regional pulmonary ventilation using dynamic hyperpolarised-(3)He-MRI] Quantitative Untersuchung der Lungenventilation mittels dynamischer MRT von hochpolarisiertem Helium-3. Fortschr Röntgenstr: 2004; 176 1399 1408
22. Woods JC, Choong CK, Yablonskiy DA et al. Hyperpolarized 3He diffusion MRI and histology in pulmonary emphysema. Magn Reson Med: 2006; 56 1293 1300
23. Kirby M, Mathew L, Wheatley A et al. Chronic obstructive pulmonary disease: longitudinal hyperpolarized (3)He MR imaging. Radiology: 2010; 256 280 289
24. Tetzlaff R, Eichinger M. Magnetresonanztomographie der Atembewegung und Lungenfunktion. Radiologe: 2009; 49 712 719
25. Bauman G, Lutzen U, Ullrich M et al. Pulmonary functional imaging: qualitative comparison of Fourier decomposition MR imaging with SPECT/CT in porcine lung. Radiology: 2011; 260 551 559
26. Morley M, Molony CM, Weber TM et al. Genetic analysis of genome-wide variation in human gene expression. Nature: 2004; 430 743 747
27. Moffatt MF, Gut IG, Demenais F et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med: 2010; 363 1211 1221
28. Vestbo J, Anderson W, Coxson HO et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J: 2008; 31 869 873
29. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med: 2010; 363 1128 1138
30. Agusti A, Calverley PM, Celli B et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res: 2010; 11 122
31. Singh D, Edwards L, Tal-Singer R et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res: 2010; 11 77
32. Lomas DA, Silverman EK, Edwards LD et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J: 2009; 34 95 102
33. Cho MH, Boutaoui N, Klanderman BJ et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet: 2010; 42 200 202
34. Foreman MG, Kong X, DeMeo DL et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol: 2011; 44 316 322
35. Singh D, Fox SM, Tal-Singer R et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax: 2011; 66 489 495
36. Banauch GI, Brantly M, Izbicki G et al. Accelerated spirometric decline in New York City firefighters with alpha-antitrypsin deficiency. Chest: 2010; 138 1116 1124
37. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc: 2009; 6 543 545
38. de Torres JP, Cote CG, Lopez MV et al. Sex differences in mortality in patients with COPD. Eur Respir J: 2009; 33 528 535
39. Lomas DA, Silverman EK, Edwards LD et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax: 2008; 63 1058 1063
40. Dickens JA, Miller BE, Edwards LD et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res: 2011; 12 146
41. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J: 2006; 27 822 832
42. Borg GA. Perceived exertion. Exerc Sport Sci Rev: 1974; 2 131 153
43. Bestall JC, Paul EA, Garrod R et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax: 1999; 54 581 586
44. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 1998; 158 1557 1565
45. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J: 2004; 23 832 840
46. Taube C, Lehnigk B, Paasch K et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2000; 162 216 220
47. Taube C, Rydzy L, Eich A et al. Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. Respir Med: 2011; 105 316 321
48. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med: 2004; 350 1005 1012
49. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med: 1991; 85 25 31
50. Jones PW. Activity limitation and quality of life in COPD. COPD: 2007; 4 273 278
51. Jones PW, Brusselle G, Dal Negro RW et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med: 2011; 105 57 66
52. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med: 2008; 359 1543 1554
53. Meguro M, Barley EA, Spencer S et al. Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest: 2007; 132 456 463
54. Jones PW, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. Eur Respir J: 2009; 34 648 654
55. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med: 2011; 11 42
56. Dodd JW, Hogg L, Nolan J et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax: 2011; 66 425 429
57. Wechsler ME, Kelley JM, Boyd IO et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med: 2011; 365 119 126
58. Dressel H, de la Motte D, Reichert J et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med: 2008; 102 962 969
59. Powell H, Murphy VE, Taylor DR et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet: 2011; 378 983 990
60. Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med: 2011; 364 1695 1707
61. Otulana BA, Wenzel SE, Ind PW et al. A Phase 2b Study Of Inhaled Pitrakinra, An Il-4/il-13 Antagonist, Successfully Identified Responder Subpopulations Of Patients With Uncontrolled Asthma. American Journal of Respiratory and Critical Care Medicine: 2011; 183 A6179
62. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med: 2011; 365 1088 1098
63. Dweik RA, Boggs PB, Erzurum SC et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med: 2011; 184 602 615
64. Takayama G, Arima K, Kanaji T et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol: 2006; 118 98 104
65. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax: 2005; 60 740 746
66. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med: 1996; 154 876 880
67. Gosens R, Zaagsma J, Meurs H et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res: 2006; 7 73
68. Gosens R, Bos IS, Zaagsma J et al. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med: 2005; 171 1096 1102
69. Ohta S, Oda N, Yokoe T et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy: 2010; 40 1266 1275
70. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr Opin Pulm Med: 2006; 12 60 67
71. Park HW, Yang MS, Park CS et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy: 2009; 64 778 783
72. Bateman ED, Kornmann O, Schmidt P et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol: 2011; 128 315 322
73. Iwamoto H, Yokoyama A, Shiota N et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J: 2008; 31 1379 1380
74. Magnussen H, Bugnas B, van Noord J et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med: 2008; 102 50 56
75. Kerstjens HA, Disse B, Schroder-Babo W et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol: 2011; 128 308 314
76. Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med: 2010; 363 1715 1726